Pharma stock signs in-licensing agreement with Biocon; Shares jump 6%

Synopsis: A licensing deal for Semaglutide across 26 countries, with launches planned post-2026 patent expiry. Q2FY26 revenue grew 14% to ₹1,354 crore, while profit increased 20% to ₹260 crore, supported by strong branded generics exposure and global reach.

The shares of the pharmaceutical gained up to 6 percent in today’s trading session after the company signed an in-licensing agreement with Biocon for marketing Semaglutide in 26 countries.

With a market capitalization of Rs 34,357.30 crore, the shares of Ajanta Pharma Ltd were trading at Rs 2,750.00 per share, increasing around 3.13 percent as compared to the previous closing price of Rs 2,666.45 apiece.

Licensing Agreement

The shares of Ajanta Pharma Ltd have seen positive movement after announcing that it has entered into an in-licensing agreement with Biocon Ltd. for Semaglutide, a GLP-1 receptor agonist. 

As per the agreement, Biocon will supply Semaglutide to Ajanta, granting exclusive marketing in 23 countries and semi-exclusive rights in 3 countries across Africa, the Middle East, and Central Asia. 

Semaglutide, the GLP-1 receptor agonist, is used to improve blood sugar control in adults. Its patent is set to expire in most target markets in March 2026. Ajanta plans to launch the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.

Commenting on the agreement, Yogesh Agrawal, Managing Director, Ajanta Pharma Ltd., said, “GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. We are excited to partner with Biocon for Semaglutide and take this important therapy to the markets where Ajanta has a strong on-ground presence and deep reach. We are confident of building Semaglutide into a meaningful and high-growth brand across these countries in the years ahead.”

Financial & Other Highlights

The company reported steady financial improvement in Q2FY26, revenue increased by 14 percent from Rs 1,187 crore in Q2FY25 to Rs 1,354 crore in Q2FY26, indicating consistent demand and execution. Further, during the same time frame, net profit increased by 20 percent from Rs 216 crore to Rs 260 crore.

The business is heavily driven by branded generics, contributing 72% of overall revenue. India and Asia together account for over half of sales, while the US generics segment contributes 25%. With 500+ brands, 50% first-to-market launches, and 5,680+ medical representatives, the company maintains strong scale and market reach globally.

Ajanta Pharma is a specialty pharmaceutical company focused on branded generics and niche therapies. With a strong presence across India, Asia, Africa, and the US, it operates in 30+ countries, backed by a broad product portfolio, strong R&D capabilities, and a growing pipeline of differentiated formulations.

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock signs in-licensing agreement with Biocon; Shares jump 6% appeared first on Trade Brains.